^
    7d
    HAZEL 401: An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Amgen
    New P2 trial
    14d
    Evaluating the Efficacy and Safety of Teprotumumab N01 in Patients With Thyroid Eye Disease. (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, Peking University Third Hospital
    New trial
    |
    Tepezza (teprotumumab-trbw)
    15d
    Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma (clinicaltrials.gov)
    P=N/A, N=20, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2028
    Trial completion date • Trial primary completion date
    |
    everolimus • temozolomide • doxorubicin hydrochloride • pazopanib • cyclophosphamide • ifosfamide • irinotecan • temsirolimus • vincristine • daunorubicin • ganitumab (AMG 479)
    17d
    20230302: A Phase 1/2 Study to Assess AMG 732 in Healthy Subjects and Subjects with Thyroid Eye Disease (2024-514110-12-00)
    P1/2, N=19, Recruiting, Amgen Inc.
    New P1/2 trial
    1m
    18F-FAPI & FDG PET/MRI assisting the precise treatment of thyroid-related eye diseases with teprotumumab and evaluating its efficacy, a prospective study (ChiCTR2500113667)
    P=N/A, N=30, Not yet recruiting, Shanghai Tenth People's Hospital; Shanghai Tenth People's Hospital
    New trial
    |
    Tepezza (teprotumumab-trbw)
    1m
    Clinical Efficacy of Teprotumumab in the Treatment of Thyroid-Associated Ophthalmopathy: A Multicenter Prospective Real-World Study (ChiCTR2500112460)
    P=N/A, N=550, Not yet recruiting, Eye and ENT hospital of Fudan University; Eye and ENT hospital of Fudan University
    New trial
    |
    Tepezza (teprotumumab-trbw)
    1m
    A prospective, randomized controlled study evaluating the efficacy and safety of Teprotumumab versus glucocorticoids in the treatment of thyroid eye disease patients with dysthyroid optic neuropathy (ChiCTR2500112153)
    P=N/A, N=62, Not yet recruiting, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine; Shanghai Ninth People’s Hospital, Shanghai Jiao Tong Universit
    New trial
    |
    Tepezza (teprotumumab-trbw)
    1m
    A Multicenter Clinical Trial Evaluating the Efficacy and Safety of Teprotumumab in Thyroid-Associated Ophthalmopathy (TAO) Patients with Clinical Activity Score (CAS) <3 and Radiographically Active Disease (ChiCTR2500111604)
    P=N/A, N=111, Not yet recruiting, Guangdong Provincial People's Hospital; Guangdong Provincial People's Hospital
    New trial
    |
    Actemra IV (tocilizumab) • Tepezza (teprotumumab-trbw)
    1m
    Evaluation of efficacy and safety of teprotumumab combined with glucocorticoids in the treatment of moderate to severe active thyroid eye disease (ChiCTR2500114188)
    P4, N=30, Not yet recruiting, Tianjin Medical University General Hospital; Tianjin Medical University General Hospital
    New P4 trial
    |
    Tepezza (teprotumumab-trbw)
    1m
    A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Teprotumumab (AMG 632) Administered Intravenously in Healthy Chinese Participants (clinicaltrials.gov)
    P1, N=20, Completed, Amgen | Active, not recruiting --> Completed
    Trial completion
    |
    Tepezza (teprotumumab-trbw)
    1m
    Unveiling bioactive compounds in kola nut seeds: GC-MS identification and computational analysis for anticancer potential. (PubMed, Front Nutr)
    From these, 15 bioactive compounds, including scopolin, picropodophyllin, catechin, yohimbine, squalene, campesterin, epicatechin, stigmasterol, p-coumaric acid, quinoline, methyl linoleate, methyl oleate, DTB-spdione, theobromine, and caffeine, were shortlisted for in silico docking studies...Based on enhanced fractionations, our study provides an expanded chemical profile of kola nut seeds and suggests that selected phytochemicals may serve as promising candidates for anticancer drug development. Further experimental validation is warranted to translate these insights into therapeutic applications.
    Journal
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    picropodophyllin (AXL1717)
    2ms
    HZNP-TEP-402: TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study (clinicaltrials.gov)
    P4, N=313, Completed, Amgen | Active, not recruiting --> Completed
    Trial completion
    |
    Tepezza (teprotumumab-trbw)